Other disclosuresNSE · NEULANDLAB
Neuland Laboratories Limited
Updates
01 / The disclosure
What the company shared
Neuland Laboratories Limited has informed the Exchange regarding 'We refer to our letter dated August 14, 2026 regarding the US FDA inspection conducted at our Unit 3 manufacturing facility and would like to inform that the US FDA has issued an EIR against the inspection conducted from August 10, 2026 to August 14, 2026. The US FDA has concluded that this inspection is closed.
Exchange-provided summary Company profile
A question for your research
Read the underlying filing for the complete disclosure and any conditions not included in the exchange summary.
The evidence
Read the source excerpts
PDF text extraction is queued. The summary above comes from the exchange listing.
Source & verificationView the disclosure trail
- Summary method
- Exchange-provided text; no generated financial figures
- Exchange identifier
- 106817859
- First collected
- 14 Oct 2026, 21:49 IST
- PDF extraction
- pending
You’ve reached the end of this disclosure.